• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对重症/危重症新型冠状病毒肺炎的多学科、三维及个体化综合治疗

Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19.

出版信息

Liver Res. 2020 Sep;4(3):109-117. doi: 10.1016/j.livres.2020.08.001. Epub 2020 Aug 25.

DOI:10.1016/j.livres.2020.08.001
PMID:32864178
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7445583/
Abstract

Severe/critical cases account for 18-20% of all novel coronavirus disease 2019 (COVID-19) patients, but their mortality rate can be up to 61.5%. Furthermore, all deceased patients were severe/critical cases. The main reasons for the high mortality of severe/critical patients are advanced age (>60 years old) and combined underlying diseases. Elderly patients with comorbidities show decreased organ function and low compensation for damage such as hypoxia and inflammation, which accelerates disease progression. The lung is the main target organ attacked by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) while immune organs, liver, blood vessels and other organs are damaged to varying degrees. Liver volume is increased, and mild active inflammation and focal necrosis are observed in the portal area. Virus particles have also been detected in liver cells. Therefore, multidisciplinary teams (MDTs) and individualized treatment plans, accurate prediction of disease progression and timely interventions are vital to effectively reduce mortality. Specifically, a "multidisciplinary three-dimensional management, individualized comprehensive plan" should be implemented. The treatment plan complies with three principles, namely, multidisciplinary management of patients, individualized diagnosis and treatment plans, and timely monitoring and intervention of disease. MDT members are mainly physicians from critical medicine, infection and respiratory disciplines, but also include cardiovascular, kidney, endocrine, digestion, nerve, nutrition, rehabilitation, psychology and specialty care. According to a patient's specific disease condition, an individualized diagnosis and treatment plan is formulated (one plan for one patient). While selecting individualized antiviral, anti-inflammatory and immunomodulatory treatment, we also strengthen nutritional support, psychological intervention, comprehensive rehabilitation and timely and full-course intervention to develop overall and special nursing plans. In response to the rapid progression of severe/critical patients, MDT members need to establish a three-dimensional management model with close observation and timely evaluation. The MDT should make rounds of the quarantine wards both morning and night, and of critical patient wards nightly, to implement "round-the-clock rounds management", to accurately predict disease progression, perform the quick intervention and prevent rapid deterioration of the patient. Our MDT has cumulatively treated 77 severe/critical COVID-19 cases, including 62 (80.5%) severe cases and 15 (19.5%) critical cases, with an average age of 63.8 years. Fifty-three (68.8%) cases presented with more than one underlying disease and 65 (84.4%) severe cases recovered from COVID-19. The average hospital stay of severe/critical cases was 22 days, and the mortality rate was 2.6%, both of which were significantly lower than the 30-40 days and 49.0-61.5%, respectively, reported in the literature. Therefore, a multidisciplinary, three-dimensional and individualized comprehensive treatment plan can effectively reduce the mortality rate of severe/critical COVID-19 and improve the cure rate.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7536/7445583/d75f86593c6a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7536/7445583/d75f86593c6a/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7536/7445583/d75f86593c6a/gr1.jpg
摘要

重型/危重型病例占新型冠状病毒肺炎(COVID-19)患者总数的18% - 20%,但其死亡率可达61.5%。此外,所有死亡患者均为重型/危重型病例。重型/危重型患者死亡率高的主要原因是高龄(>60岁)和合并基础疾病。合并基础疾病的老年患者器官功能下降,对缺氧和炎症等损伤的代偿能力低,这加速了疾病进展。肺是严重急性呼吸综合征冠状病毒2(SARS-CoV-2)攻击的主要靶器官,而免疫器官、肝脏、血管等器官也受到不同程度的损伤。肝脏体积增大,在门静脉区可见轻度活动性炎症和局灶性坏死。肝细胞中也检测到病毒颗粒。因此,多学科团队(MDT)和个体化治疗方案、准确预测疾病进展并及时干预对于有效降低死亡率至关重要。具体而言,应实施“多学科三维管理,个体化综合方案”。治疗方案遵循三个原则,即患者的多学科管理、个体化诊疗方案以及疾病的及时监测和干预。MDT成员主要是来自重症医学、感染和呼吸学科的医生,但也包括心血管、肾脏、内分泌、消化、神经、营养、康复、心理和专科护理等方面的人员。根据患者的具体病情制定个体化诊疗方案(一人一案)。在选择个体化的抗病毒、抗炎和免疫调节治疗的同时,我们还加强营养支持、心理干预、综合康复以及及时和全程干预,以制定全面和特殊的护理计划。针对重型/危重型患者病情快速进展的情况,MDT成员需要建立密切观察和及时评估的三维管理模式。MDT应早晚对隔离病房进行查房,夜间对重症患者病房进行查房,实施“全天候查房管理”,以准确预测疾病进展,进行快速干预并防止患者病情迅速恶化。我们的MDT累计治疗了77例重型/危重型COVID-19病例,其中包括62例(80.5%)重型病例和15例(19.5%)危重型病例,平均年龄为63.8岁。53例(68.8%)病例合并有一种以上基础疾病,65例(84.4%)重型病例从COVID-19中康复。重型/危重型病例的平均住院天数为22天,死亡率为2.6%,均显著低于文献报道的30 - 40天和49.0% - 61.5%。因此,多学科、三维和个体化的综合治疗方案可有效降低重型/危重型COVID-19的死亡率并提高治愈率。

相似文献

1
Multidisciplinary, three-dimensional and individualized comprehensive treatment for severe/critical COVID-19.针对重症/危重症新型冠状病毒肺炎的多学科、三维及个体化综合治疗
Liver Res. 2020 Sep;4(3):109-117. doi: 10.1016/j.livres.2020.08.001. Epub 2020 Aug 25.
2
Therapeutic effects of multidisciplinary individualized treatment for COVID-19 patients: the experience of a supporting medical team in Wuhan.新型冠状病毒肺炎患者多学科个体化治疗的疗效:武汉一支支援医疗队的经验
J Thorac Dis. 2023 Dec 30;15(12):6813-6820. doi: 10.21037/jtd-23-1428. Epub 2023 Dec 26.
3
Surgical intensive care - current and future challenges?外科重症监护——当前及未来的挑战?
Qatar Med J. 2020 Jan 13;2019(2):3. doi: 10.5339/qmj.2019.qccc.3. eCollection 2019.
4
Sepsis Care Pathway 2019.2019年脓毒症护理路径
Qatar Med J. 2019 Nov 7;2019(2):4. doi: 10.5339/qmj.2019.qccc.4. eCollection 2019.
5
Low Humoral Immune Response and Ineffective Clearance of SARS-Cov-2 in a COVID-19 Patient With CLL During a 69-Day Follow-Up.一名慢性淋巴细胞白血病(CLL)合并新型冠状病毒肺炎(COVID-19)患者在69天随访期间的低体液免疫反应及对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的清除无效
Front Oncol. 2020 Jul 3;10:1272. doi: 10.3389/fonc.2020.01272. eCollection 2020.
6
A Multidisciplinary NHS COVID-19 Service to Manage Post-COVID-19 Syndrome in the Community.多学科 NHS COVID-19 服务,用于管理社区中的新冠后综合征。
J Prim Care Community Health. 2021 Jan-Dec;12:21501327211010994. doi: 10.1177/21501327211010994.
7
Nutrition management for critically and acutely unwell hospitalised patients with coronavirus disease 2019 (COVID-19) in Australia and New Zealand.澳大利亚和新西兰针对患有2019冠状病毒病(COVID-19)的危重症和急症住院患者的营养管理。
Nutr Diet. 2020 Sep;77(4):426-436. doi: 10.1111/1747-0080.12636.
8
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Induced Cardiovascular Syndrome: Etiology, Outcomes, and Management.严重急性呼吸综合征冠状病毒2(SARS-CoV-2)诱发的心血管综合征:病因、预后及管理
Cureus. 2020 Jun 10;12(6):e8543. doi: 10.7759/cureus.8543.
9
The Effectiveness of Integrated Care Pathways for Adults and Children in Health Care Settings: A Systematic Review.综合护理路径在医疗环境中对成人和儿童的有效性:一项系统评价。
JBI Libr Syst Rev. 2009;7(3):80-129. doi: 10.11124/01938924-200907030-00001.
10
A severe COVID-19 case with schizophrenia as well as other chronic diseases.患有精神分裂症和其他慢性病的严重 COVID-19 病例。
Braz J Med Biol Res. 2021 Jan 15;54(3):e10426. doi: 10.1590/1414-431X202010426. eCollection 2021.

引用本文的文献

1
Effect of oral nutrition supplements on anthropometric and functional parameters among community-dwelling older adults: a systematic review and meta-analysis of randomized controlled trials.口服营养补充剂对社区居住老年人人体测量和功能参数的影响:一项随机对照试验的系统评价和荟萃分析
BMC Nutr. 2025 Feb 13;11(1):42. doi: 10.1186/s40795-025-01010-8.
2
Nursing Interventions Related to the Need for Oxygenation in Severe COVID-19 Disease in Hospitalized Adults: A Retrospective Study.住院成人重症新型冠状病毒肺炎患者氧疗相关护理干预措施的回顾性研究
Nurs Rep. 2024 Oct 22;14(4):3126-3137. doi: 10.3390/nursrep14040227.
3
Association of Lung CT Findings in Coronavirus Disease 2019 (COVID-19) With Patients' Age, Body Weight, Vital Signs, and Medical Regimen.

本文引用的文献

1
Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage.中性粒细胞与淋巴细胞比值可预测 2019 冠状病毒病重症患者的早期病情。
J Transl Med. 2020 May 20;18(1):206. doi: 10.1186/s12967-020-02374-0.
2
[The protocol for prevention, diagnosis and treatment of liver injury in coronavirus disease 2019].[新型冠状病毒肺炎肝损伤防治专家共识]
Zhonghua Gan Zang Bing Za Zhi. 2020 Mar 20;28(3):217-221. doi: 10.3760/cma.j.cn501113-20200309-00095.
3
Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies.
2019冠状病毒病(COVID-19)肺部CT表现与患者年龄、体重、生命体征及治疗方案的相关性
Front Med (Lausanne). 2022 Jun 30;9:912752. doi: 10.3389/fmed.2022.912752. eCollection 2022.
通过尸体核心活检对 2019 年新型冠状病毒病(COVID-19)的病理学研究。
Mod Pathol. 2020 Jun;33(6):1007-1014. doi: 10.1038/s41379-020-0536-x. Epub 2020 Apr 14.
4
Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy.抗凝治疗与伴有凝血功能障碍的严重 2019 冠状病毒病患者的死亡率降低相关。
J Thromb Haemost. 2020 May;18(5):1094-1099. doi: 10.1111/jth.14817. Epub 2020 Apr 27.
5
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma.5 例危重症 COVID-19 患者接受恢复期血浆治疗。
JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.
6
Gross examination report of a COVID-19 death autopsy.一份新冠死亡病例尸检大体检查报告。
Fa Yi Xue Za Zhi. 2020 Feb;36(1):21-23. doi: 10.12116/j.issn.1004-5619.2020.01.005. Epub 2020 Feb 25.
7
Prominent changes in blood coagulation of patients with SARS-CoV-2 infection.SARS-CoV-2 感染患者凝血功能的显著变化。
Clin Chem Lab Med. 2020 Jun 25;58(7):1116-1120. doi: 10.1515/cclm-2020-0188.
8
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.中国武汉成人 COVID-19 住院患者的临床病程和死亡危险因素:一项回顾性队列研究。
Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11.
9
[Novel coronavirus pneumonia (COVID-19) CT distribution and sign features].[新型冠状病毒肺炎(COVID-19)的CT分布及征象特点]
Zhonghua Jie He He Hu Xi Za Zhi. 2020 Apr 12;43(4):321-326. doi: 10.3760/cma.j.cn112147-20200217-00106.
10
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局:一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.